Prescient Therapeutics Ltd (PTX):企業の財務・戦略的SWOT分析

◆英語タイトル:Prescient Therapeutics Ltd (PTX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH140529FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Prescient Therapeutics Ltd (Prescient Therapeutics), formerly Virax Holdings Ltd, is a biotechnology company which develops novel medicines for cancer treatment. The company is investigating OmniCAR, an immune receptor platform that controls T-cell activity and multi-antigen targeting with a single cell product for combined approach to formulate novel chimeric antigen receptor T (CAR-T) to treat cancer and other diseases. Its pipeline products include PTX-100, a compound which blocks geranylgeranyl transferase-1 (GGT-1), a cancer growth enzyme; and PTX-200, a novel PH domain inhibitor that obstructs protein kinase B or AKT signalling, which develops breast, ovarian cancer and leukemia. The company’s OmniCAR platform is built on technology licensed from University of Pennsylvania and SpyTag/SpyCatcher binding system licensed from Oxford University to develop improved CAR-T approaches for treating cancer and solid tumors. Prescient Therapeutics is headquartered in Melbourne, Victoria, Australia.

Prescient Therapeutics Ltd Key Recent Developments

Jan 18,2021: Prescient announces internal OmniCAR programs for three next-gen CAR-T therapies
Dec 17,2020: Leading International Blood Cancer Specialist Professor H. Miles Prince AM joins Prescient Scientific Advisory Board
Dec 09,2020: Prescient extending testing in COVID-19 antiviral screening program with Doherty Institute
Oct 20,2020: Prescient Therapeutics : September 2020 quarterly update and Appendix 4C
Oct 12,2020: Shedding Light on Prescient Therapeutics’ (PTX) personalised cancer treatments

This comprehensive SWOT profile of Prescient Therapeutics Ltd provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Prescient Therapeutics Ltd including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Prescient Therapeutics Ltd – Key Information
Prescient Therapeutics Ltd – Overview
Prescient Therapeutics Ltd – Key Employees
Prescient Therapeutics Ltd – Key Employee Biographies
Prescient Therapeutics Ltd – Key Operational Heads
Prescient Therapeutics Ltd – Major Products and Services
Prescient Therapeutics Ltd – History
Prescient Therapeutics Ltd – Company Statement
Prescient Therapeutics Ltd – Locations And Subsidiaries
Prescient Therapeutics Ltd
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Prescient Therapeutics Ltd – Business Description
Prescient Therapeutics Ltd – Corporate Strategy
Prescient Therapeutics Ltd – SWOT Analysis
SWOT Analysis – Overview
Prescient Therapeutics Ltd – Strengths
Prescient Therapeutics Ltd – Weaknesses
Prescient Therapeutics Ltd – Opportunities
Prescient Therapeutics Ltd – Threats
Prescient Therapeutics Ltd – Key Competitors

Section 3 – Company Financial Performance Charts

Prescient Therapeutics Ltd – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Prescient Therapeutics Ltd, Key Information
Prescient Therapeutics Ltd, Key Ratios
Prescient Therapeutics Ltd, Share Data
Prescient Therapeutics Ltd, Major Products and Services
Prescient Therapeutics Ltd, History
Prescient Therapeutics Ltd, Key Employees
Prescient Therapeutics Ltd, Key Employee Biographies
Prescient Therapeutics Ltd, Key Operational Heads
Prescient Therapeutics Ltd, Other Locations
Prescient Therapeutics Ltd, Subsidiaries
Prescient Therapeutics Ltd, Key Competitors
Prescient Therapeutics Ltd, SWOT Analysis
Prescient Therapeutics Ltd, Ratios based on current share price
Prescient Therapeutics Ltd, Annual Ratios
Prescient Therapeutics Ltd, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Prescient Therapeutics Ltd (PTX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Suntory Beverage & Food Limited:企業の戦略・SWOT・財務情報
    Suntory Beverage & Food Limited - Strategy, SWOT and Corporate Finance Report Summary Suntory Beverage & Food Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • ExlService Holdings, Inc.:企業の戦略・SWOT・財務情報
    ExlService Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary ExlService Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Asian Citrus Holdings Ltd (73):企業の財務・戦略的SWOT分析
    Asian Citrus Holdings Ltd (73) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Veolia Environnement S.A.:企業の戦略・SWOT・財務分析
    Veolia Environnement S.A. - Strategy, SWOT and Corporate Finance Report Summary Veolia Environnement S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • ImmusanT Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary ImmusanT Inc (ImmusanT) is a clinical stage biotechnology company that discovers, develops and delivers peptide-based immune therapies for the treatment of patients with autoimmune diseases. The company develops its therapeutic vaccines using its epitope-specific immuno-therapy (ESIT) platfo …
  • NorthWestern Corporation (NWE)-エネルギー分野:企業M&A・提携分析
    Summary NorthWestern Corporation, doing business as NorthWestern Energy, is an integrated electric utility which generates, transmits, and distributes electricity and distributes natural gas in South Dakota, Nebraska and Montana. It produces energy from wind, hydro, natural gas, and coal-fired sourc …
  • PPG Industries, Inc.:企業の戦略・SWOT・財務情報
    PPG Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary PPG Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Georgia Power Co (GPW)-エネルギー分野:企業M&A・提携分析
    Summary Georgia Power Company (Georgia Power), a subsidiary of the Southern Power Company, generates, transmits, distributes and sells electricity. The company produces electricity using various sources of energy such as coal, nuclear, solar, gas and hydro. It supplies electricity in Georgia and to …
  • Sosei Heptares (4565):企業の財務・戦略的SWOT分析
    Summary Sosei Heptares(Sosei) formerly known as Sosei Group Corp, is a biopharmaceutical company that develops and commercializes drugs. The company’s pipeline products include NorLevo, NVA237, QVA149 and SO-1105. Its NorLevo product is an oral emergency contraceptive; and SO-1105 is an antifungal a …
  • Lucigen Corp:医療機器:M&Aディール及び事業提携情報
    Summary Lucigen Corp (Lucigen), a subsidiary of LGC Ltd, is a medical device company that discovers, manufactures, and commercializes molecular biology product. The company’s products comprise competent cells, nextgen seq, enzymes, cloning systems, PCR and amplification, cloning test kits and vector …
  • Selective Insurance Group, Inc. (SIGI):企業の財務・戦略的SWOT分析
    Selective Insurance Group, Inc. (SIGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • VA Tech Wabag Ltd (WABAG):企業の財務・戦略的SWOT分析
    Summary VA Tech Wabag Ltd (VA Tech) is engaged in the planning, design, installation and operation of water and wastewater plants. The company’s services include water treatment, desalination, waste water treatment, water reclamation, and sludge treatment. Its projects comprise Sundarijal Water Trea …
  • CoLucid Pharmaceuticals Inc (CLCD)-製薬・医療分野:企業M&A・提携分析
    Summary CoLucid Pharmaceuticals Inc (CoLucid) is a pharmaceutical company that conducts research and develops new therapies. CoLucid’s lead product candidate Lasmiditan (COL-144), is an oral tablet that penetrates the central nervous system and selectively targets 5-HT1F receptors expressed in the t …
  • X-ELIO Energy SL:電力:M&Aディール及び事業提携情報
    Summary X-ELIO Energy SL (X-ELIO), formerly Gestamp Solar, a subsidiary of Corporacion Gestamp S.L. is an alternative energy company that operates utility scale photovoltaic power plants. The company constructs, designs, installs, develops, and maintains solar photovoltaic plants. Its development, c …
  • Dairygold Co-operative Society Ltd:企業の戦略的SWOT分析
    Dairygold Co-operative Society Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Georgetown University-製薬・医療分野:企業M&A・提携分析
    Summary Georgetown University (GU) is an academic and research institution which offers educational services. It provides undergraduate and graduate degree programs in the fields of law, medical, medical residencies, business administration and public policy degrees, post-doctoral positions, special …
  • Central Securities Corp (CET):企業の財務・戦略的SWOT分析
    Summary Central Securities Corp (Central Securities) is a financial service provider that provides investment services. The company offers investment management services and stock investment related services. It invests on convertible preferred stocks, bonds, preferred stocks, convertible bonds, war …
  • CNX Resources Corp (CNX):企業の財務・戦略的SWOT分析
    CNX Resources Corp (CNX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Aeon Delight Co Ltd:企業の戦略・SWOT・財務情報
    Aeon Delight Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Aeon Delight Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Abdullah Al-Othaim Markets Co.
    Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report Summary Abdullah Al-Othaim Markets Co. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆